Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Torres, T (Author) Other; Paiva Lopes, MJ (Author) Other; Goncalo, M (Author) Other; Claro, C (Author) Other; Oliveira, M (Author) Other; Gomes, J (Author) Other; Vieira, AP (Author) Other; Amoedo, P (Author) Other; Alpalhao, M (Author) Other; Nogueira, M (Author) Other; Santiago, F (Author) Other; Henrique, M (Author) Other; Amaro, C (Author) Other; Esteves, T (Author) Other; Alves, J (Author) Other; Cerejeira, D (Author) Other; Mendes Bastos, P (Author) Other; Pestana, M (Author) Other; Ramos, L (Author) Other; Rocha, J (Author) Other; Carvalho, R (Author) Other; Teixeira, L (Author) ICBAS; Selores, M (Author) Other; Mota, A (Author) Other; Filipe, P (Author) Other

Journal

Title: Journal of Dermatological Treatment

Vol. 33

Pages: 2554-2559

ISSN: 0954-6634

Publisher: Taylor & Francis

Indexing

ISI Web of Knowledge - 5 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00W-2QR

DOI: 10.1080/09546634.2022.2035309

Abstract (EN): Introduction Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older. Methods This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD. Results A total of 169 patients were enrolled, with a mean disease duration of 22.75 (+/- 11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported. Conclusion Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6